This LIF/gp130/JAK/STAT3-mediated growth inhibitory signaling is conserved in different MTC cell lines regardless of the mutational status of RET [109], and could also be activated by interleukin-1β via the Raf/MEK/ERK pathway [92]. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.